Hwangryunhaedoktang in adult patients with Atopic Dermatitis: a randomised, double-blind, placebo-controlled, two-centre trial - study protocol

Abstract

BackgroundAtopic Dermatitis is a chronic relapsing eczematous skin disease with increasing prevalence and rising costs. It has a clear impact on a patient's quality of life. Many patients are worried about the use of usual care techniques, such as corticosteroids and antihistamine due to the widespread fear of adverse effects. Complementary and alternative medical approaches have been employed to relieve symptoms of Atopic Dermatitis. Hwangryunhaedoktang is among the most strongly preferred and widely used herbal medicines for Atopic Dermatitis in Korea, as it causes very few serious adverse effects.We aim to establish basic clinical efficacy and safety data for Hwangryunhaedoktang, which is approved as an herbal medication by the Korean Food and Drug Administration, in adult patients with Atopic Dermatitis.Methods/DesignsThis study is a randomised, double blind, placebo-controlled, two-centre trial with two parallel arms (Hwangryunhaedoktang and a placebo). The diagnosis of Atopic Dermatitis will be made according to the criteria of Hanifin and Rajka by two different Oriental medicine doctors. We will include participants experiencing typical conditions of intermittent or continuous Atopic Eczema for six or more months. Participants will receive Hwangryunhaedoktang or a placebo-drug for eight weeks. The total duration of each arm is eleven weeks. Each participant will be examined for signs and symptoms of Atopic Dermatitis before and after taking medication. A follow-up to evaluate the maintenance of safety will be performed two weeks after the final administration of medication.DiscussionThis trial will utilize high quality trial methodologies in accordance with consolidated standards of reporting trials guidelines. It will provide evidence for the clinical efficacy and safety evaluation of Hwangryunhaedoktang in adult patients with Atopic Dermatitis. Moreover, we will also employ health-related quality of life questionnaires to assess the changes in quality of life.Trial registrationCurrent Controlled Trials ISRCTN26218532

A Family-Engaged Educational Program for Atopic Dermatitis: A Seven-Year, Multicenter Experience in Daegu-Gyeongbuk, South Korea

“…Most of the responses to the follow-up telephone survey about overall effect on life and disease progression were positive, but several parts of the questionnaire showed a pattern of neutral responding (e.g., using complementary and alternative medicine, learning attitude and ability, and the patient's relationship with friends and family members). With regard to the results about complementary and alternative medicines, almost 60% of the total Korean population has been treated by traditional Korean medicine for chronic intractable diseases like AD 8 . This may be because many Korean people still believe that Oriental medicine is safer than Western medicine.…”

KM110329 in adult patients with atopic dermatitis: a randomised, double-blind, placebo-controlled, multicentre trial – study protocol

“…A study protocol for the treatment of AD using the herbal medicine Hwangryunhaedoktang has already been published [ 17 ], however, the present study has several distinctive features. First, this will be the first trial to investigate the efficacy of the functional food KM110329 for the treatment of AD.…”

Inhibition of eukaryotic elongation factor-2 confers to tumor suppression by a herbal formulation Huanglian-Jiedu decoction in human hepatocellular carcinoma

“…According to Medical Secretes of an Official (wai tai mi yao in Chinese) and Prescriptions for Emerent Reference (zhou hou fang in Chinese), HLJDD was mainly used to remove heat and scavenge toxins from human body, which represents the symptoms of fever and diarrhea ). Its treatment on jaundice, inflammation and hypertension is well accepted in the early days in China, and it is now also approved by Ministry of Health, Labour and Welfare of Japan and Korean Food and Drug Administration, for palliative cares and atopic dermatitis treatment (Kim et al, 2011;Okumi and Koyama, 2014). Our clinical practice with HLJDD also indicates that this formula may be effective in treating patients with hepatocellular carcinoma.…”